{"id":"gefitinib-and-pemetrexed-platinum","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Rash/acneiform dermatitis"},{"rate":"30-50","effect":"Diarrhea"},{"rate":"30-50","effect":"Nausea/vomiting"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"1-3","effect":"Interstitial lung disease"},{"rate":"5-15","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gefitinib is a tyrosine kinase inhibitor that blocks epidermal growth factor receptor (EGFR) signaling, particularly effective in EGFR-mutant non-small cell lung cancers. Pemetrexed is an antifolate that inhibits multiple enzymes in nucleotide synthesis, and platinum agents (cisplatin or carboplatin) cause DNA crosslinking and damage. The combination leverages targeted therapy with conventional chemotherapy for enhanced anti-tumor effect.","oneSentence":"This combination uses gefitinib to inhibit EGFR signaling in lung cancer cells while pemetrexed/platinum chemotherapy provides additional cytotoxic activity through multiple mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:50.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC) with EGFR mutations"}]},"trialDetails":[{"nctId":"NCT03944772","phase":"PHASE2","title":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-06-25","conditions":"Non-Small Cell Lung Cancer","enrollment":247},{"nctId":"NCT04322890","phase":"PHASE2","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-04-16","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation","enrollment":6000},{"nctId":"NCT01982955","phase":"PHASE1, PHASE2","title":"Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2013-12-23","conditions":"Non-small Cell Lung Cancer","enrollment":88},{"nctId":"NCT01951469","phase":"PHASE3","title":"Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Non-small Cell Lung Cancer, Brain Metastases, EGFR Mutation","enrollment":160},{"nctId":"NCT01544179","phase":"PHASE3","title":"A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-03-15","conditions":"Non-Small Cell Lung Cancer","enrollment":265},{"nctId":"NCT04115410","phase":"","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-07-01","conditions":"Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events","enrollment":4724},{"nctId":"NCT03374280","phase":"PHASE2","title":"Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC","status":"UNKNOWN","sponsor":"Guangzhou Medical University","startDate":"2016-12-01","conditions":"Non Small Cell Lung Cancer","enrollment":178},{"nctId":"NCT03381066","phase":"PHASE3","title":"A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2018-04-10","conditions":"Completely Resected NSCLC With Common EGFR Mutations","enrollment":225},{"nctId":"NCT02031601","phase":"PHASE4","title":"Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2014-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":250},{"nctId":"NCT01769066","phase":"PHASE2, PHASE3","title":"Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC","status":"COMPLETED","sponsor":"Fudan University","startDate":"2009-12","conditions":"NSCLC","enrollment":117},{"nctId":"NCT01928160","phase":"PHASE2","title":"Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib","status":"WITHDRAWN","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2014-06","conditions":"Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT01017874","phase":"PHASE3","title":"A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-11","conditions":"Non Small Cell Lung Cancer","enrollment":236},{"nctId":"NCT01579630","phase":"PHASE2, PHASE3","title":"Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2011-03","conditions":"NSCLC","enrollment":52},{"nctId":"NCT00891579","phase":"PHASE2","title":"Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations","status":"COMPLETED","sponsor":"Chinese Society of Lung Cancer","startDate":"2009-02","conditions":"Non Small Cell Lung Cancer","enrollment":161},{"nctId":"NCT00409006","phase":"PHASE2","title":"Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-02","conditions":"Non-small Cell Lung Cancer","enrollment":70},{"nctId":"NCT01192243","phase":"PHASE2","title":"Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2009-12","conditions":"Toxicity, Non-small Cell Lung Cancer","enrollment":68},{"nctId":"NCT01066195","phase":"PHASE3","title":"Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2008-05","conditions":"Non-small Cell Lung Cancer","enrollment":129}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gefitinib and Pemetrexed/platinum","genericName":"Gefitinib and Pemetrexed/platinum","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses gefitinib to inhibit EGFR signaling in lung cancer cells while pemetrexed/platinum chemotherapy provides additional cytotoxic activity through multiple mechanisms. Used for Non-small cell lung cancer (NSCLC) with EGFR mutations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}